Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three immunoglobulin preparations for intravenous infusion were compared in vivo to determine their relative protective capacity against several gram-negative and gram-positive pathogens. Polyglobin N is a conventional IgG concentrate. Psomaglobin N is identical in formulation to Polyglobin N but is prepared from the plasma of donors who have naturally high levels of antibody to lipopolysaccharide antigens of Pseudomonas aeruginosa. IgGMA is a conventional IgG concentrate containing 12% IgG and 16% IgA. In a murine model of burn wound sepsis the three IgG preparations were similarly protective against three or ten strains of P. aeruginosa. Psomaglobin N and Polyglobin N were significantly (p less than or equal to 0.015) more protective than IgGMA against six of ten and three of ten strains of P. aeruginosa, respectively. In a murine model of Streptococcus pneumoniae type 3 pneumonia, the three Ig preparations were similarly protective. IgGMA was significantly more protective (p less than or equal to 0.025) than Psomaglobin N and Polyglobin N against Salmonella typhimurium in murine peritonitis. However, the mean protective dose (PD50) of the two later preparations was less than or equal to 20 mg/kg body weight. In models of peritonitis both Psomaglobin N and Polyglobin N were more protective than IgGMA (p less than or equal to 0.004) against Haemophilus influenzae b, Klebsiella pneumoniae, Serratia marcescens 06:H3 and group B Streptococcus types 1b and 1c. Psomaglobin N and ciprofloxacin were employed to treat established polymicrobial murine burn wound sepsis resulting from contamination of the burn site with mixtures of P. aeruginosa and Staphylococcus aureus.(ABSTRACT TRUNCATED AT 250 WORDS)
Infection 1987
PMID:[Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model]. 311 21

A microbiological analysis of 102 patients suffering from cystic fibrosis was conducted over a 22 month period. 20 microbial species with the following incidence were identified: Pseudomonas aeruginosa: 83.4%; Candida albicans: 29.4%; Staphylococcus aureus: 24.5%; Staphylococcus epidermidis: 11.8%; Haemophilus influenzae: 11.8%; Streptococcus pneumoniae; 6.9%; Pseudomonas maltophilia: 6.8%; Aspergillus fumigatus: 5.9%. Other species were present in less than 5% of the patients. In the majority of specimens with P. aeruginosa, more than one type (up to six) was detectable. These strains were identical in colony appearance, O-serotype and pyocin-type. Quantitative analysis revealed concentrations of colony-forming units of 10(7) to 10(9) for P. aeruginosa, 10(6) to 10(8) for P. maltophilia, 10(4) to 10(7) for S. aureus, 10(4) to 10(6) for S. epidermidis and 10(4) to 10(7) for C. albicans in the majority of specimens. Significant differences were observed in the time periods during which the pathogens persisted in the patients. Maximum persistence was observed for P. aeruginosa. P. maltophilia and A. fumigatus had about similar persistence rates, which were lower than those for P. aeruginosa but above those for S. aureus and H. influenzae. S. epidermidis was eliminated within shorter periods than S. aureus. C. albicans, although the second most frequent microorganism identified, showed a very low persistence rate. The microbiological analysis confirms results from other research centers (high incidence of P. aeruginosa), but reveals significant regional differences as well (Pseudomonas cepacia not detectable, higher incidence of P. maltophilia and C. albicans). This underlines the necessity for detailed qualitative and quantitative microbiological analysis of sputa from cystic fibrosis patients as a prerequisite for rational analysis of etiological, epidemiological and therapeutical aspects of cystic fibrosis.
Infection
PMID:Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. 311

The identification of respiratory pathogens (e. g. Haemophilus influenzae, Streptococcus pneumoniae) is impaired by the presence of large quantities of Pseudomonas aeruginosa, as is the case in the sputum specimens of cystic fibrosis patients. A procedure has been evaluated whereby the selective inhibition of the proliferation of P. aeruginosa is achieved by a broad spectrum pyocin, whereas the growth of H. influenzae is not influenced. This technique has been tested over a two year period resulting in a significantly augmented rate of identification of H. influenzae.
Infection
PMID:Selective procedure to isolate haemophilus influenzae from sputa with large quantities of Pseudomonas aeruginosa. 311 1

Data from the literature and the authors' experiences were used to review aspects of antibiotic therapy of patients with cystic fibrosis; attention was paid to in vitro antimicrobial susceptibility tests and assessment of therapy directed against mucoid Pseudomonas aeruginosa. The heterogeneity of P. aeruginosa within single sputa with respect to antibiotic susceptibility is stressed. Quantitative viable counts of bacteria based on an analysis of homogenised sputum is recommended. The mode of in vivo growth of mucoid P. aeruginosa is discussed to explain the survival of hypersusceptible P. aeruginosa in vivo, and the clinical benefit observed in the absence of a significant reduction of the pathogen. The value of ceftazidime in the treatment of exacerbations due to Haemophilus influenzae is emphasised. The social benefits from oral administration of ciprofloxacin also emphasises that the patient's quality of life must also be considered.
Infection
PMID:Rational parameters for antibiotic therapy in patients with cystic fibrosis. 311 4

Three hundred and one patients with maxillary sinusitis participated in a double-blind, randomized study at 11 ENT-clinics in Europe. Sinusitis was diagnosed by the presence of at least two signs and symptoms and sinus X-ray showing more than 6 mm swelling of the maxillary mucosa. A microbiological specimen was obtained by intrasinusal aspiration. The patients were randomly assigned to treatment either with bacampillin 800 mg b. i. d. or with amoxicillin 500 mg t. i. d. for ten days. The most frequently isolated bacteria were Haemophilus influenzae (94 strains), Streptococcus pneumoniae (66 strains) and Branhamella catarrhalis (12 strains). In 96 of the patients, no microorganisms could be isolated. Beta-lactamase production was found in one H. influenzae strain and in three B. catarrhalis strains. Two hundred and seventy-one patients could be evaluated for efficacy at the follow-up visit day 8-25. The overall clinical outcome was the same in both treatment groups. Adverse events such as skin reactions and upper and lower gastrointestinal reactions occurred in 17.4% of the amoxicillin treated patients and in 10.8% of the bacampicillin treated patients (p = 0.101).
Infection
PMID:Efficacy of penicillin treatment in purulent maxillary sinusitis. A European multicenter trial. 314 Dec 90

We have studied the in-vitro activity of erythromycin, vancomycin and pristinamycin against 1,006 clinical isolates comprising streptococci, staphylococci, Neisseria gonorrhoeae, Haemophilus influenzae and anaerobes. In-vitro studies show pristinamycin to inhibit staphylococci and streptococci, including erythromycin highly-resistant organisms, at a concentration of less than or equal to 0.78 mg/l. Although pristinamycin's mean MIC for streptococci is higher than that of erythromycin, pristinamycin is bactericidal, whereas erythromycin is bacteristatic against Streptococcus agalactiae and oral streptococci. Enterococci were less uniformly susceptible to pristinamycin: 58 of the 94 Enterococcus faecalis tested were resistant (MIC greater than or equal to 3.12 mg/l). 14 of the 15 isolates of Enterococcus faecium were inhibited by less than or equal to 1.56 mg/l pristinamycin. Pristinamycin showed poor activity against Haemophilus influenzae (mode MIC 1.56 and MIC90 of 3.12 mg/l) but all except two of the 100 Neisseria gonorrhoeae tested were inhibited by less than or equal to 0.78 mg/l pristinamycin. Pristinamycin inhibited all nine Clostridium spp. at less than or equal to 0.39 mg/l and 38 of 40 strains of anaerobic gram-positive cocci at less than or equal to 0.78 mg/l. It was less effective against the Bacteroides fragilis group: (MIC90 3.12 mg/l). Pristinamycin had poor bactericidal activity against the anaerobes tested.
Infection 1988
PMID:Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin. 314 52

One hundred seventy-five clinical isolates of Haemophilus influenzae (including 74 beta-lactamase-producing strains) were examined for susceptibility to ampicillin, cefonicid, cefamandole, cefuroxime and cefotaxime. Cefonicid and cefamandole exhibited similar activity against ampicillin-susceptible strains (MIC90 = 0.2 mg/l for both antibiotics); cefuroxime was slightly less active (MIC90 = 0.01 mg/l). However, cefonicid, cefuroxime and cefotaxime were all more active against beta-lactamase-producing H. influenzae than cefamandole (MIC90 = 1.0 mg/l for cefonicid, MIC90 = 2.0 mg/l for cefuroxime, MIC90 = 0.01 mg/l for cefotaxime, MIC90 = 5.0 mg/l for cefamandole). One hundred twenty-five of the 175 isolates were also tested for susceptibility to cefonicid and cefamandole by disc diffusion technique and a plot of zone diameter vs. MIC was analyzed for the beta-lactamase-producing strains.
Infection
PMID:In vitro activity of second and third generation cephalosporins against ampicillin susceptible and resistant haemophilus influenzae. 326 30

The distribution of respiratory tract infections (RTI) among the general population is not uniform. The incidence in neonates and the elderly (older than 65) is 2 to 3 times higher than that in adults. Examinations to determine the responsible pathogen are conducted in less than 1% of cases of RTI. The overall incidence of Haemophilus influenzae and Streptococcus pneumoniae in hospitalized patients amounts to 13 to 27%. The incidences of Staphylococcus aureus, Klebsiella and Pseudomonas aeruginosa in intensive care units are approximately 20% each. The management of the disease should be based on an aetiological diagnosis, and must take the individual patient's condition into account. Examination of the sputum or bronchial rinsing fluid is still the most reliable form of diagnosis, however, a sufficient number of quantitative methods must be applied. In hospitalized--and especially intensive care--patients these methods are often successful in isolating H. influenzae and pneumococci which we cannot afford to ignore as pathogens.
Infection 1987
PMID:[Incidence of deep respiratory tract infections]. 330 84

Infection is the most important cause of mortality in leucopenic patients. A broad spectrum antibiotic therapy is imperative in febrile and neutropenic patients. In a multicentric study we have used ceftazidime (100 mg/kg/d) and netilmicin (6 mg/kg/d) in 88 children (fever greater than or equal to 38.5 degrees C, neutropenia less than 500/mm3) treated for acute leukemias (59), non Hodgkin lymphomas (13) or solid tumors (16). Median age was 7 years (2 months-16 years). In patients who continued to remain febrile, vancomycin (40 mg/kg/d) was added after 48 hours. The effective treatment was continued until a neutrophil count greater than 1,000/mm3. The first combination (ceftazidime + netilmicin) was effective in 64 children (73%) and the second combination (ceftazidime + netilmicin + vancomycin) in 11 patients. Bacteria were isolated in 39 children: Escherichia coli: 9, Staphylococcus epidermidis: 9, Staphylococcus aureus: 8, Streptococcus: 6, Pseudomonas aeruginosa: 3, Streptococcus pneumoniae: 1, Haemophilus: 1, Klebsiella pneumoniae: 1, Proteus: 1, Serratia: 1, Flavobacterium: 1. In these 39 patients, 30 became apyretic with ceftazidime and netilmicin and 6 after vancomycin. All blood culture were negative after the first combination. The median duration of antibiotic therapy was 14 days (5-9 days: 28, 10-20 days: 43, greater than 20 days: 17). There were no death, no superinfection. Tolerance was good without kidney or liver or biological perturbation. We conclude that the combination ceftazidime and netilmicin is effective in neutropenic children.
 ...
PMID:[Treatment of febrile episodes in neutropenic children by ceftazidime combined with netilmicin. Results of a multicenter study apropos of 88 cases]. 330 78

51 hospitalised patients with acute purulent exacerbations of chronic bronchitis were treated for ten days with two daily 1 g doses of the orally absorbed pro-drug cefuroxime axetil. However, some patients were still infected with Haemophilus influenzae or Branhamella catarrhalis at follow-up, and sputum purulence remained. Clinical results were "excellent" or "good" in 60% of the evaluable patients one week after the end of the treatment. Mean peak serum concentrations averaged 12.8 mg/l with mean peak sputum concentrations of 1.8 mg/l. The MIC90 value for H. influenzae was 4 mg/l. Three patients discontinued cefuroxime because of unwanted gastrointestinal drug effects, and three because of insufficient improvement. These results do not suggest that this compound is indicated for such patients.
Infection
PMID:Cefuroxime axetil in acute purulent exacerbations of chronic bronchitis. 331 21


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>